Upadacitinib (Rinvoq)

JAKI drugs used for autoimmune disease including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. 

Inhibits JAK

RINVOQ  

DOSAGE FORMS AND STRENGTHS

Extended-release tablets: 15 mg, 30 mg, and 45 mg

DOSAGE AND ADMINISTRATION

Prior to treatment update immunizations and consider evaluating for active

and latent tuberculosis, viral hepatitis, hepatic function, and pregnancy

status

Avoid initiation or interrupt RINVOQ if absolute lymphocyte count is less

than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3,

or hemoglobin level is less than 8 g/dL.

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic

Axial Spondyloarthritis

The recommended dosage is 15 mg once daily.

Atopic Dermatitis

Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and

Adults Less Than 65 Years of Age: Initiate treatment with 15 mg orally

once daily. If an adequate response is not achieved, consider increasing the

dosage to 30 mg orally once daily.

Adults 65 Years of Age and Older: Recommended dosage is 15 mg once

daily.

 Severe Renal Impairment: Recommended dosage is 15 mg once daily.

Ulcerative Colitis

Adults: The recommended induction dosage is 45 mg once daily for 8

weeks. The recommended maintenance dosage is 15 mg once daily. A

maintenance dosage of 30 mg once daily may be considered for patients

with refractory, severe, or extensive disease. Discontinue RINVOQ if

adequate therapeutic response is not achieved with the 30 mg dosage. Use

the lowest effective dosage needed to maintain response. (2.6)

 See the Full Prescribing Information for the recommended dosage in

patients with renal or hepatic impairment and for dosage modification due

to drug interactions.

Crohn’s Disease

Adults: The recommended induction dosage is 45 mg once daily for 12

weeks. The recommended maintenance dosage is 15 mg once daily. A

maintenance dosage of 30 mg once daily may be considered for patients

with refractory, severe, or extensive disease. Discontinue RINVOQ if an

adequate therapeutic response is not achieved with the 30 mg dosage. Use

the lowest effective dosage needed to maintain response. 

 See the Full Prescribing Information for the recommended dosage in

patients with renal or hepatic impairment and for dosage modification due

to drug interactions.